Stratman discusses individualized eczema care, expanding treatment options, and the potential of precision medicine to guide therapy.
Quiz|Articles|October 25, 2026
Dermatology Times Spot Test: October 25, 2026
Author(s)Shannon Heaning, Content Associate
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This edition explores hedgehog pathway inhibitor use in advanced basal cell carcinoma (BCC), including treatment selection, adverse event management, and response assessment. Test your knowledge, then read
Do you have a set of quiz questions to share? Contact editor Shannon Heaning at Sheaning
According to Shannon Trotter, DO, which characteristic of vismodegib may make it preferable for a patient with irregular meal timing?
In the roundtable poll, which adverse event was most frequently identified as leading patients to discontinue HHI therapy?
What key difference distinguished the response criteria used in the BOLT trial from those used in ERIVANCE?
Advertisement
Related to this article
Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
Explore trending plant oils in skincare and haircare, plus 2026’s hottest actives like ectoin and hypochlorous acid—balancing glow, barrier repair, and irritation risks.
Houston dermatology clinicians compared severity scoring, JAK inhibitor safety data, and psychosocial counseling strategies across 3 alopecia areata patient cases.
Preview the trial data dermatology NPs and PAs will dissect in small-group sessions on AD, psoriasis, and type 2 disease at Horizons in Advanced Practice.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Debate JAK Inhibitor Selection in Alopecia Areata
2
Menopause and the Skin: Recognizing Changes Beyond Aging
3
Social Media Mythbusters: Can Face Taping Really Prevent Wrinkles?
4
Type 2 Inflammation, Growth Curve, and HS Guidance for Advanced Practice
5